Principles and practice of intraperitoneal chemotherapy for ovarian cancer

被引：68
作者：
Fujiwara, K.
Armstrong, D.
Morgan, M.
Markman, M.
机构：
[1] Saitama Med Univ, Dept Obstet & Gynecol, Moroyama, Saitama 3500495, Japan
[2] Johns Hopkins Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA
[3] Johns Hopkins Kimmel Canc Ctr, Dept Gynecol & Obstet, Baltimore, MD USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Med Oncol, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2007年 / 17卷 / 01期
关键词：
intraperitoneal chemotherapy; ovarian cancer;
D O I：
10.1111/j.1525-1438.2007.00809.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Intraperitoneal (IP) chemotherapy has been studied for years to improve the survival of patients with ovarian cancer. Recently, the result of Gynecologic Oncology Group 172 trial comparing IP versus intravenous administration of cisplatin-based chemotherapy was published, demonstrating the improvement of survival benefit in favor of the IP arm. This trial is the third trial that showed a survival benefit on IP chemotherapy. The National Cancer Institute (NCI) and Gynecologic Oncology Group have done a meta-analysis on the results of these three US trials and other phase III trials of IP versus intravenous chemotherapy, and significant improvement of survival was shown with IP therapy. Based on this meta-analysis, NCI has released a clinical announcement encouraging the gynecological oncology community to consider IP chemotherapy as the standard treatment for optimally debulked advanced ovarian cancer patients. However, there still are controversial issues regarding the use of IP chemotherapy. It is important to understand how IP chemotherapy works to solve those issues in the future. In this review article, we discuss the principles and clinical aspects of IP chemotherapy and also discuss the current problems and future perspectives in IP chemotherapy.
引用
收藏
页码：1 / 20
页数：20
相关论文
共 75 条
[51]   Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin - A Sankai Gynecology Study Group (SGSG) study [J].
Miyagi, Y ;
Fujiwara, K ;
Kigawa, J ;
Itamochi, H ;
Nagao, S ;
Aotani, E ;
Terakawa, N ;
Kohno, I .
GYNECOLOGIC ONCOLOGY, 2005, 99 (03) :591-596
[52]  
Morgan RJ, 2003, CLIN CANCER RES, V9, P5896
[53]   Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up [J].
Morgan, RJ ;
Braly, P ;
Cecchi, G ;
Leong, L ;
Shibata, S ;
Margolin, K ;
Somlo, G ;
McNamara, M ;
Longmate, J ;
Schinke, S ;
Raschko, J ;
Nagasawa, S ;
Kogut, N ;
Parker, P ;
Stein, A ;
Cho, J ;
Smith, E ;
Coluzzi, P ;
Najera, L ;
Johnson, D ;
Womack, E ;
Doroshow, JH .
GYNECOLOGIC ONCOLOGY, 1999, 75 (03) :419-426
[54]   Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: Long-term follow-up [J].
Morgan, RJ ;
Braly, P ;
Leong, L ;
Shibata, S ;
Margolin, K ;
Somlo, G ;
McNamara, M ;
Longmate, J ;
Schinke, S ;
Raschko, J ;
Nagasawa, S ;
Kogut, N ;
Najera, L ;
Johnson, D ;
Doroshow, JH .
GYNECOLOGIC ONCOLOGY, 2000, 77 (03) :433-438
[55]   Intraperitoneal mitoxantrone or floxuridine: Effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy - A randomized phase II study by the Southwest Oncology Group [J].
Muggia, FM ;
Liu, PY ;
Alberts, DS ;
Wallace, DL ;
OToole, RV ;
Terada, KY ;
Franklin, EW ;
Herrer, GW ;
Goldberg, DA ;
Hannigan, EV .
GYNECOLOGIC ONCOLOGY, 1996, 61 (03) :395-402
[56]  
MUGGIA FM, 1991, CANCER CHEMOTH PHARM, V28, P241
[57]  
NEDERMAN T, 1984, CANCER CHEMOTH PHARM, V13, P131
[58]   PHASE-I PHASE-II STUDY OF INTRAPERITONEAL MITOXANTRONE IN REFRACTORY OVARIAN-CANCER [J].
OZA, AM ;
HUININK, WT ;
DUBBELMAN, R ;
SOEPENBERG, O ;
MANDJES, I ;
AARTSEN, E ;
MCVIE, JG .
ANNALS OF ONCOLOGY, 1994, 5 (04) :343-347
[59]  
Ozols RF, 2006, NEW ENGL J MED, V354, P1641
[60]   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J].
Ozols, RF ;
Bundy, BN ;
Greer, BE ;
Fowler, JM ;
Clarke-Pearson, D ;
Burger, RA ;
Mannel, RS ;
DeGeest, K ;
Hartenbach, EM ;
Baergen, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3194-3200
12345678